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Background: Thrombotic thrombocytopenic purpura (TTP) is frequently associated with renal abnormalities, but
there have been few reports about renal abnormalities in patients with hereditary TTP. In particular, little is known
about the long-term prognosis of patients with childhood-onset congenital TTP.
Case presentation: We report a Japanese patient with congenital TTP (Upshaw–Schulman syndrome) who was
followed for 19 years after initiation of hemodialysis when he was 22 years old. At the age of 6 years, the first
episode of purpura, thrombocytopenia, and proteinuria occurred without any precipitating cause. He underwent
living-related donor kidney transplantation from his mother, but the graft failed after 5 months due to recurrence of
TTP. Even after resection of the transplanted kidney and resumption of regular hemodialysis, TTP became refractory
to infusion of fresh frozen plasma (FFP). Therefore, splenectomy was performed and his disease remained in
remission for 10 years. However, TTP recurred at the age of 39 years. Plasma activity of ADAMTS13 (a disintegrin
and metalloprotease with thrombospondin type I domain 13) was less than 3%, while ADAMTS13 inhibitor was not
detected (< 0.5 Bethesda units/mL). The patient died suddenly after hemodialysis at the age of 41 years.
Subsequent genetic analysis of this patient and his parents revealed two different heterozygous mutations of
ADAMTS13, including a missense mutation in exon 26 (c.3650T>C causing p.I1217T) inherited from his father and a
missense mutation in exon 21 (c.2723G>A causing p.C908Y) inherited from his mother. The former mutation has
not been detected before in Japan, while the latter mutation is common in Japan. A retrospective review showed
that serum C3 levels were consistently low while C4 levels were normal during follow-up, and C3 decreased much
further during each episode of TTP.
Conclusion: Congenital TTP was diagnosed from the clinical, biochemical, and genetic findings. Infusion of FFP
controlled each thrombotic episode, but the effect was limited and of short duration. Review of the complement
profile in this patient suggested that a persistently low serum C3 level might be associated with refractory TTP and
a worse renal prognosis.
Keywords: Congenital thrombotic thrombocytopenic purpura, ADAMTS13 (a disintegrin and metalloprotease with
thrombospondin type I domain 13), Chronic hemodialysis, Complement activation, C3, Alternative pathway* Correspondence: kokims-frz@umin.ac.jp
1Nephrology Center, Toranomon Hospital, Tokyo, Japan
6Nephrology Center, Toranomon Hospital Kajigaya, 1-3-1, Kajigaya, Takatu-ku,
Kawasaki-shi, Kanagawa-ken 213-0015, Japan
Full list of author information is available at the end of the article
© 2013 Mise et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the ord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Mise et al. BMC Nephrology 2013, 14:156 Page 2 of 5
http://www.biomedcentral.com/1471-2369/14/156Background
Thrombotic thrombocytopenic purpura (TTP) is a rare
disorder characterized by thrombocytopenia and
microangiopathic hemolytic anemia. Congenital TTP
has been reported to be associated with severe deficiency
of the plasma activity of ADAMTS13 (a disintegrin and
metalloprotease with thrombospondin type I domain
13), which is reduced to <5% of normal by mutation of
the ADAMTS13 gene, and this is known as the
Upshaw–Schulman syndrome (USS) [1,2]. Deficiency of
ADAMTS13 activity can also be caused by inhibitory
antibodies targeting ADAMTS13, leading to acquired
TTP. ADAMTS13 is a metalloproteinase that specifically
cleaves multimeric von Willebrand factor (VWF) [2],
while VWF is a large glycoprotein that is essential for
platelet adhesion and aggregation under high shear
stress conditions [3]. ADAMTS13 is mainly synthesized
in the liver by stellate cells [4,5]. In addition, it is
expressed by the podocytes and endothelium of the renal
glomeruli, where podocyte-derived ADAMTS13 might
have a local protective effect in the high shear stress
glomerular microcirculation [6].
TTP is often associated with renal abnormalities and
there have been some reports about such abnormalities
in TTP patients, but few about hereditary TTP. In
particular, there is little information about the long-
term prognosis of patients with childhood-onset
congenital TTP [7]. Here, we report a Japanese man
with congenital TTP confirmed by genetic analysis,
who was followed up for 19 years after initiation of
hemodialysis.
Case presentation
A 22-year-old man was admitted to our hospital for
renal transplantation. He was the third of five children
of non-consanguineous parents. There was no history of
severe neonatal jaundice. Purpura of the lower extre-
mities, thrombocytopenia, and proteinuria occurred
without any precipitating cause at the age of 6 years, and
hemolytic uremic syndrome (HUS) was diagnosed. This
episode subsided spontaneously without treatment, but
there were repeated recurrences and his renal function
deteriorated gradually. In 1990, at the age of 22 years,
hemodialysis was started for end-stage renal disease
(ESRD) along with the occurrence of cerebral infarction.
After 4 months, living-related kidney transplantation
was performed with his mother as the donor. Immuno-
suppressive therapy included prednisolone (70 mg daily),
cyclosporine (420 mg daily), antilymphocyte globulin
(1 g daily), and azathioprine (100 mg daily). At 7 days
after surgery, he developed thrombocytopenia (23.1 to
1.8 × 104/μL) and hemolytic anemia (Hb: 10.3 to 8.2 g/dL),
along with an increase of serum creatinine (1.1 to 2.1 mg/dL),
lactate dehydrogenase (LDH: 208 to 785 IU), and totalbilirubin (0.4 to 2.2 mg/dL). Haptoglobulin was decreased
to 3.4 mg/dL. Serum levels of C3 and C4 were also
decreased (C3: 63.0 to 51.7 mg/dL, normal range; 83
to 177 mg/dL, C4: 34.4 to 22.9, normal range; 15 to
45 mg/dL). Activation of HUS was suspected to have
been caused by cyclosporine, so it was switched to
deoxyspergualin (200 mg daily). After methylprednisolone
pulse therapy (500 mg/day for 3 days) and infusion of
fresh frozen plasma (FFP) (800 mL × 5 days), HUS sub-
sided temporarily. However, there was frequent relapse of
HUS, so azathioprine was changed to mizoribine and
muromonab-CD3 was administered. Plasma exchange or
infusion FFP was effective for terminating each episode of
HUS. After 50 days, cerebral hemorrhage occurred,
followed by gastrointestinal bleeding at 90 days. Then
HUS recurred with thrombocytopenia and hemolytic
anemia, which was refractory to plasma exchange or infu-
sion of FFP, and his renal function deteriorated gradually.
In May 1991, removal of the kidney graft was performed
and hemodialysis was restarted. Examination of the
resected kidney showed thrombi, endothelial cell swelling,
and numerous red blood cells in the glomeruli and small
arteries (Figure 1). After nephrectomy, jejunal bleeding
was treated by transcatheter arterial embolization of an
arteriovenous malformation in the superior mesenteric
artery territory.
Even after hemodialysis was resumed, transient
ischemic attacks and cerebral infarction occurred every
time his platelet count decreased spontaneously,
subsiding in response to infusion of FFP. However, TTP
became refractory to FFP in 1998. Because indium plate-
let scintigraphy showed high uptake in the spleen and
his platelets had a short lifespan (1.76 days), splenec-
tomy was performed in order to prevent excessive platelet
destruction. Thereafter, thrombotic episodes requiring the
infusion of FFP did not occur for 10 years until 2008.
During this remission period, the serum level of C3 was
always lower than normal and serum C4 was normal,
while the C3 level decreased much further with each
episode of TTP. When cerebral infarction with throm-
bocytopenia occurred again at the age of 39 years, plasma
ADAMTS13 activity was less than 5% of normal, as mea-
sured by the FRETS-VWF73 assay [8], while ADAMTS13
inhibitor was negative (<0.5 Bethesda units/mL) [9]. USS
was diagnosed because he had severe deficiency of
ADAMTS13 activity without any detectable inhibitor in
conjunction with appropriate clinical criteria. Although
the thrombotic episodes subsided following infusion of
FFP, he died suddenly after hemodialysis in 2010 at the
age of 41 years. After the patient’s death, we measured
plasma ADAMTS13 activity and inhibitor in his parents
using a chromogenic ELISA [10]. Both of them had
ADAMTS13 activity around 30% of normal and the
inhibitor was negative.
Figure 1 Renal histopathological findings. A, B: Fibrin thrombi in
small arteries (arrows) and a glomerulus containing numerous red
blood cells (A: Heidenhain's azan trichrome stain, B: Periodic acid
methenamine silver stain × 400). C: Endothelial cell swelling (arrows)
(Heidenhain's azan trichrome stain × 400).
Figure 2 Pedigree of the index patient with genetic haplotypes
and plasma activity of ADAMTS13 (a disintegrin and
metalloprotease with thrombospondin type I domain 13).
Squares represent males and circles represent females. Plasma
ADAMTS13 activity (%) is shown under the circles and squares.
Mutations of the ADAMTS13 gene are shown as one-letter amino
acid abbreviations numbered from the initial Met codon. The arrow
indicates the index patient. The mother and father of the index
patient are both asymptomatic carriers. Abbreviations P: patient, ND:
not determined.
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After obtaining consent from his parents, genetic ana-
lysis of the patient and parents was performed with the
approval of the Ethics Committees of Nara Medical
University, the National Cerebral and Cardiovascular
Center, and Toranomon Hosipital. Genetic analysis ofthe patient was carried out at the National Cerebral and
Cardiovascular Center using DNA extracted from the
resected spleen. For his parents, analysis was performed
at the Department of Blood Transfusion Medicine of
Nara Medical University.
It was demonstrated that the patient had compound
heterozygous mutations of ADAMTS13, comprising a
missense mutation in exon 26 (c.3650T>C causing p.
I1217T) that was inherited from his father and a mis-
sense mutation in exon 21 (c.2723G>A causing p.C908Y)
inherited from his mother. A diagnosis of congenital
TTP (USS) was confirmed by these findings (Figure 2).
Discussion
It is widely recognized that TTP is associated with renal
abnormalities, with renal failure occurring secondary to
damage caused by microthrombi that develop because of
decreased plasma ADAMTS13 activity. The common
renal manifestations of TTP are proteinuria and hema-
turia. Acute renal failure (ARF) affects 11% of patients
with severe congenital TTP and often recurs with
exacerbation of this disease [7]. Although ARF requiring
dialysis was reported to be less frequent (0–9.7%) in four
series of patients with acquired TTP [11-13], the
percentage of patients with congenital TTP who need
regular dialysis is unclear. Tsai et al. [7] reported that
five out of nine patients with USS progressed to ESRD
requiring dialysis, and three of them had episodes of
ARF. Therefore, repeated episodes of ARF may be
associated with progression to ESRD.
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exacerbation of congenital TTP, plasma exchange is the
standard treatment. In patients with relapsing and/or
refractory TTP, splenectomy can be effective. The me-
chanism is assumed to be that splenectomy decreases
autoantibody production by removing a large reservoir
of B lymphocytes [14], which is a reasonable explanation
for patients with acquired TTP and elevated levels of
ADAMTS13 inhibitor. However, Snider et al. [15] repor-
ted a patient with relapsing and refractory congenital
TTP who remained in complete clinical remission for 4
years after splenectomy. In our patient, remission of
TTP persisted for 10 years after splenectomy, but the
effect was limited. The mechanism by which splenec-
tomy improves congenital TTP is unknown, although it
is possible that a state like idiopathic thrombocytopenia
purpura (ITP) might have coexisted with TTP in our
patient because his short platelet lifespan was compatible
with ITP. Since TTP remained in remission for 10 years
after splenectomy without the need for FFP, this case
shows that splenectomy can be a useful option for relaps-
ing/refractory congenital TTP. There has only been one
previous case report of renal transplantation for chronic
renal failure in a patient with congenital TTP, and the
graft showed early failure due to disease recurrence [16].
In our case, the graft also failed due to chronic relapsing
TTP only 5 months after transplantation. Therefore, renal
transplantation may not a feasible option for ESRD in
patients with congenital TTP.
Several mutations of the ADAMTS13 gene have been
reported in congenital TTP. It is thought that specific
ADAMTS13 mutations are more common among
certain ethnicities [17]. Fujimura et al. [17] evaluated 43
USS patients in Japan and found ADAMTS13 mutations
that were specific to Japanese individuals with congenital
TTP. The present patient had p.C908Y with maternal
inheritance, which is one of the common ADAMTS13
mutations found in Japanese patients [17]. However, the
patient also had p.I1271T (inherited from his father) and
this has not been reported before in Japanese patients,
was although it is consistent with the missense muta-
tion reported by Park et al. [18] in a Korean patient
who had congenital TTP complicating moyamoya
disease. Fujimura et al. [17] reported that two out of 43
patients with congenital TTP progressed to ESRD
requiring dialysis. One of them was homozygous for
c.414 + 1G > A, while the other was heterozygous for
c.1885delT (paternal inheritance) and p.C908Y (maternal
inheritance). However, these mutations were also detected
in some of their TTP patients without progression to
dialysis. In fact, five of the 43 patients had the p.C908Y
mutation that was detected in our case, but only one of
them progressed to dialysis during follow-up. Therefore,
as Tsai et al. [7] concluded, the relation betweenADAMTS13 mutation and the renal prognosis remains
uncertain [17].
With regard to the occurrence of renal impairment in
this patient, it may be important to focus on the comple-
ment system. Ruiz-Torres et al. [19] studied thrombotic
microangiopathy patients with congenital ADAMTS13
deficiency and patients with ADAMTS 13 inhibitors,
and they reported that four of out of six patients (66%)
showed a moderate decrease of C3 in the acute phase,
which was indicative of complement activation and con-
sumption. They hypothesized that platelet microthrombi
caused activation of the alternative pathway in patients
with ADAMTS13 deficiency. Moreover, Noris et al. [20]
reported 2 sisters who had the same compound hetero-
zygous ADAMTS13 mutations, while one sister also had
a heterozygous mutation of the gene encoding comple-
ment factor H, a plasma factor that inhibits activation of
the alternative pathway. The second sister had severe
disease, with renal involvement requiring chronic dialy-
sis, and eventually died of a stroke. She had subnormal
serum C3 levels and normal C4 levels. In addition, one of
the four congenital TTP patients reported by Ruiz-Torres
et al. had a subnormal C3 level even in remission and her
serum creatinine level was 5.73 mg/dL, suggesting ESRD.
Considering these reports, some patients with congenital
TTP may have persistently low C3 levels that may be asso-
ciated with a worse renal prognosis. The findings in our
case seem to support this hypothesis. If a persistently de-
pressed C3 level and normal C4 level, indicating selective
activation of the alternative pathway, is one of the causes
of severe TTP, the anti-C5 monoclonal antibody eculi-
zumab may be an effective treatment for refractory TTP.
In fact, Chapin et al. [21] reported that eculizumab was
effective for refractory TTP, so use of eculizumab might
have been a good treatment option in our case.
Conclusion
We encountered a male patient with congenital TTP who
remained on hemodialysis for 19 years. His ADAMTS13
gene had two mutations, which were p.I1217T (the first
report of this mutation in Japan) and p.C908Y (common
in Japan). Infusion of FFP was effective for controlling
thrombotic episodes, but the improvement was limited
and of short duration. The profile of complement compo-
nents in this patient suggests an association of persistently
low serum C3 level with refractory TTP and a worse renal
prognosis.
Consent
Written informed consent was obtained from the patient’s
parents for the genetic analyses, as well as for publication
of this case report and any accompanying images. We
could not obtain written consent from the patient himself
because he was already dead when we wrote this paper.
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